Temozolomide Plus Radiotherapy Improves Survival in Non-Co-Deleted Glioma
Combination treatment of temozolomide plus radiotherapy improves survival in non-co-deleted gliomas.
The FDA has granted full approval of Avastin for the treatment of glioblastoma.
Treatment with lomustine plus bevacizumab does not show a survival advantage over treatment with lomustine alone in patients with glioblastoma.
In patients with melanoma brain metastases, overall survival has increased since 2000.